Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications TIL Cells

Publication Date: April 13, 2018

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma

TILs expanded from glioblastoma tumors of five patients recognized patient-specific mutated peptides, showing that neoepitope-specific reactivity is present in GBM-infiltrating T cells. Whole-exome sequencing of tumor and normal DNA identified private mutations, from which 15-mer mutated peptides and matching wildtype peptides were synthesized. TILs, expanded with IL-2, IL-15 and IL-21, were co-cultured with each peptide for seven days and IFN-γ, TNF-α and IL-17A were measured by ELISA. Every patient had at least some mutated peptides that triggered cytokine release with little or no response to the wildtype sequence, and CD8+ TILs dominated these responses. In patient GBM-E, TILs produce…

Download Now →

Author: Davide Valentini, Martin Rao +9 more

Publications T-Cells G-Rex®10

Publication Date: April 5, 2018

Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase

Methotrexate selection can enrich primary human CD4 T cells carrying a drug-resistance gene inserted at the CCR5 locus. Cells were electroporated with CCR5 megaTAL nuclease mRNA and transduced with an AAV6 donor carrying one of three mutant DHFR variants linked to GFP. Across ten experiments with nine healthy donors, insertion efficiency ranged from 8% to 38%. After restimulation by rapid expansion protocol, 100 nM methotrexate added on day 4 enriched gene-modified cells in seven donors from starting levels as low as 3% to as high as 45% after two weeks, and all three variants performed comparably. Edited cells kept a memory phenotype and a polyclonal TCR repertoire through selection. A l…

Download Now →

Author: Biswajit Paul, Guillermo S. Romano Ibarra +6 more

Publications CAR T Cells G-Rex®10

Publication Date: March 6, 2018

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects

A self-inactivating lentiviral vector carrying a TRAC-targeting sgRNA in its 3' long terminal repeat links CAR19 expression to CRISPR/Cas9 editing, so that T cells can be made CAR-positive and TCR-negative in one coupled process. Vector titer matched a conventional CAR19 vector (1.6 × 10^8 versus 1.5 × 10^8 per mL). On a CliniMACS Prodigy, Cas9 mRNA electroporation followed by magnetic TCRαβ depletion gave 96.9% CAR19-positive cells and 2.9 × 10^9 cells, almost 30 times the starting number. Targeted sequencing showed an indel frequency of 92.3% at TRAC, with no off-target events detected at tested sites. In mice bearing Daudi leukemia, the edited cells produced potent anti-leukemic effect…

Download Now →

Author: Christos Georgiadis, Roland Preece +10 more

Publications CAR T Cells, γδ T G-Rex®10, G-Rex®100

Publication Date: February 3, 2018

Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex® vessels and their use as chimeric antigen receptor– modified effector cells

Vγ9Vδ2 T cells can be expanded from PBMCs to clinically relevant numbers in 17 days using a two-step Zometa and K562 feeder protocol in G-Rex® vessels. PBMCs were activated for 7 days with Zometa and IL-2, then co-cultured for 10 days with irradiated K562 artificial antigen-presenting cells expressing CD64, CD86 and CD137L with OKT3 at a 1:100 ratio. Nine healthy donors reached a mean total cell expansion of 4616-fold with 89% Vγ9Vδ2 purity, and four lymphoma patient samples reached 10,995-fold with 5% AB serum. Expanded cells showed an effector memory phenotype with reduced checkpoint receptor expression. Anti-EpCAM RNA CAR-modified cells killed 100% of ovarian and squamous carcinoma tar…

Download Now →

Author: Lin Xiao, Can Chen +10 more

Publications TCR T Cells G-Rex®500M-CS

Publication Date: January 24, 2018

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules

A modular closed and semi-closed process produced clinical-scale HPV-16 E6 and E7 TCR-transduced T cells with high transduction efficiency and strong function. The 21-day process had a 7-day activation and retroviral transduction phase in culture bags, followed by a 14-day rapid expansion in a single closed gas-permeable G-Rex® vessel, and was tested on two healthy donors and four patients with epithelial cancers. Ten million transduced cells grown with allogeneic feeders yielded about 18.9 × 10^9 T cells, a 1890-fold expansion in the rapid phase, with transduction efficiencies of 64–92%. Effector memory cells dominated the product. E7 TCR cells killed 100 ± 1.9% of CASKi target cells at…

Download Now →

Author: Jianjian Jin, Nikolaos Gkitsas +6 more

Publications TCR T Cells G-Rex®24 Well Plate

Publication Date: January 1, 2018

Generation of Tumor-Specific (tg-TCR) T Cells Using CRISPR-Mediated In-Locus Insertion Combined with Endogenous TCR Knockout

Knocking out the endogenous TCR alpha and beta chains while inserting a WT1-specific transgenic TCR into the TRAC locus with CRISPR/Cas9 and an AAV template produced T cells with higher transgenic TCR expression and less chain mispairing than editing TRAC alone. Guides were screened for indel frequency, specificity and insertion rate, and off-target risk was assessed by SITE-Seq. Edited cells expanded comparably to non-edited T cells and showed low exhaustion. Loss of endogenous TCRα and β exceeded 98%, and in-locus insertion reached 70-80% without further purification. Three WT1-specific TCRs, including affinity-enhanced and natural receptors, showed robust on-target killing, degranulati…

Download Now →

Author: A. Prodeus, S. Yazinski +10 more

Publications CAR T Cells G-Rex®10

Publication Date: December 22, 2017

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells

Combining irradiated autologous activated T cells as feeders, stimulation with viral peptides instead of anti-CD3/CD28 antibodies, and a CH2CH3-free CAR vector raised CAR expression in piggyBac-engineered CD19 CAR-T cells to 51.4% ± 14% within 14 days. Feeder cells alone lifted CAR expression from 4.6% to 10.7%, and viral peptide stimulation increased it to 33.0%. Removing the spacer gave 51.4% versus 33.0% with the original vector, with 27.8 × 10^6 CAR-positive cells from 10 × 10^6 PBMCs. Products were mostly CD45RA+CCR7+; at E:T ratios of 1:50 and 1:100 they eliminated 94.7% and 87.8% of CD19+ SU/SR leukemic cells in vitro, and they improved survival of Daudi-bearing NSG mice (p < 0.…

Download Now →

Author: Daisuke Morita, Nobuhiro Nishio +12 more

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: December 20, 2017

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

Lym-1 CAR T cells, which target a conformational HLA-DR epitope on B-cell lymphomas, lysed lymphoma cells in culture and eradicated Raji xenografts in mice with activity comparable to CD19 CAR T cells. Primary T cells from healthy donors were transduced with a second-generation 4-1BB/CD3ζ construct, with efficiencies of 30% to 80%. Lym-1 and CD19 CAR T cells responded to epitope-positive Raji and Daudi cells by upregulating CD107a, secreting IFN-γ and IL-2, proliferating and lysing them, but not to epitope-negative K562 cells. In NSG mice, a single intravenous dose of 10^7 CAR T cells (50% CAR positive) given on day 7 after Raji/Luc-GFP inoculation left only background bioluminescence thr…

Download Now →

Author: Long Zheng, Peisheng Hu +6 more

Publications TIL Cells

Publication Date: November 1, 2017

A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer

Iovance's second-generation process for the tumor infiltrating lymphocyte product LN-144 shortens manufacturing from 38 to 22 days and yields a cryopreserved product with quality attributes comparable to the first-generation fresh product. Fragment culture is cut from up to 21 days in multiple bioreactors to up to 11 days in a single closed bioreactor, and harvest and wash are closed and semi-automated. Mean total viable cells were similar, at 4.10 × 10^10 for Gen 1 and 4.12 × 10^10 for Gen 2. Relative telomere length was 7.5% versus 8.4%, and Gen 2 products secreted more interferon gamma on CD3, CD28 and CD137 stimulation and showed greater T-cell receptor diversity (p = 0.008). Viabilit…

Download Now →

Author: Seth Wardell, Ian Frank +7 more

Publications VST Cells G-Rex®10

Publication Date: November 1, 2017

Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy

Autologous BK virus-specific T cell lines can be generated at clinical scale in 14 days from kidney transplant recipients with active viremia, but only when peptide-pulsed dendritic cells are used for stimulation. Direct peptide stimulation of PBMC gave fold expansions of 12.1 ± 7.4 in healthy controls and 4.6 ± 1.9 in recipients, and fewer than 50 million cells for 3 of 5 recipient lines. Dendritic cell stimulation significantly increased expansion (P = 0.042), shifted differentiation toward central memory, and improved VP1 specificity. Lines from both groups remained polyclonal, lysed only peptide-loaded autologous targets, and, unlike unmanipulated T cells, caused no xenogeneic graft-v…

Download Now →

Author: Caroline Lamarche, Julie Orio +8 more

Publications TIL Cells G-Rex®10

Publication Date: September 25, 2017

4-1BB agonist focuses CD8+ tumor-infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer

Adding an agonistic 4-1BB antibody (urelumab) to IL-2 during the initial tumor fragment culture of pancreatic ductal adenocarcinoma specimens increased tumor-infiltrating lymphocyte (TIL) yield and shifted growth toward CD8+ cells. Mean total TIL rose from 40 × 10^6 to 100 × 10^6 cells, and culture success doubled from 29% to 52%. CD8+ cells made up about 55% of CD3+ TIL, compared with 25% with IL-2 alone. The cells remained mostly effector memory without terminal differentiation, and CD8+ sequencing showed distinct clonal repertoires per condition. Sorted CD8+ TIL from both conditions recognized autologous tumor targets in an MHC class I-restricted manner, tested in two patients.

Download Now →

Author: Donastas Sakellariou-Thompson, Marie-Andrée Forget +21 more

Publications NK Cells, TIL Cells G-Rex®100M

Publication Date: August 24, 2017

Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells

A single-cell platform that links cell phenotype with real-time cytokine secretion was built from thin-bottom PDMS nanowell arrays and antibody-coated beads, and it showed that CD16-positive NK cells are rapid interferon gamma secretors. PEG grafting for 20 minutes reduced non-specific binding. Bead-based counts of IFN-γ-secreting T cells (0.40–7.8%) matched ELISPOT (0.20–11.2%), with R2 = 0.87. Simulations indicated that captured cytokine density rose with time over 0–6 h in an open well. In peripheral blood NK cells stimulated with PMA and ionomycin, secretion peaked around 50–60 minutes, and the amount and rate of secretion differed between donors. Pairs or triplets of NK cells showed…

Download Now →

Author: Xingyue An, Victor G. Sendra +9 more